A contrast medium (or contrast agent) is a chemical substance applied to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue.
The chemical composition of the contrast media determines the specific usage. The intention in the development of ultrasound contrast media is a high contrast between blood and tissues in different organs or even tumors.

See also ultrasound contrast agents, the info sheet gives an overview and more in-depth information about different types of ultrasound contrast medium.

Echogenicity is the ability of a medium to create an echo, for example to return a signal when tissue is in the path of the sound beam. The ultrasound echogenicity is dependent on characteristics of tissues or contrast agents and is measured by calculating the backscattering and transmission coefficients as a function of frequency.
The fundamental parameters that determine echogenicity are density and compressibility. Blood is two to three orders of magnitude less echogenic than tissue due to the relatively small impedance differences between red blood cells and plasma. The tissue echogenicity can be increased by ultrasound contrast agents. Encapsulated microbubbles are highly echogenic due to differences in their compressibility and density, compared to tissue or plasma.
Microbubbles are 10,000 times more compressible than red blood cells. The compressibility of air is 7.65 x 10−6 m2/N, in comparison with 4.5 x 10-11 m2/N for water (on the same order of magnitude as tissue and plasma). This impedance mismatch results in a very high echogenicity. An echo from an individual contrast agent can be detected by a clinical ultrasound system sensitive to a volume on the order of 0.004 pl.

See also Isoechogenic, Retrolenticular Afterglow, and Sonographic Features.

From Bayer Schering Pharma AG:
Echovist-200® was an effectively one-pass-only contrast medium for contrast sonography and Doppler-echocardiographic examinations for the detection, exclusion or follow-up of pathological states leading to hemodynamic changes. Because of the short intravascular life of the microparticles and microbubbles, transit through the pulmonary circulation is unusual. In cardiac evaluations Echovist-200® has been replaced by newer ultrasound contrast agents (USCA), therefore the manufacturing was discontinued.
Another range of echo contrast application is the female genital tract, in particular for the demonstration or exclusion of acquired or congenital changes of the uterine cavity and for the visualization of the Fallopian tubes and investigation of their patency.
1 g Echovist-200 granules contain 1 g D-galactose microparticles. 1 ml aqueous solution for production of the suspension contains 200 mg D-galactose.
Brand names in other countries: Ecovist.

The gas in microbubbles is highly compressible and, when subjected to the alternating compression and refraction pressures that constitute an ultrasound pulse, microbubbles oscillate at their natural frequency at which they resonate most strongly. This is determined by their size but is also influenced by the composition of the filling gas.
Air, sulfur hexafluoride, nitrogen, and perfluorochemicals are used as filling gases. Most newer ultrasound contrast agents use perfluorochemicals because of their low solubility in blood and high vapor pressure. By substituting different types of perfluorocarbon gases for air, the stability and plasma longevity of the agents have been markedly improved, usually lasting more than five minutes.

The first generation ultrasound contrast agents (UCA/USCA) do not pass the pulmonary vascular bed, and are therefore limited to the venous system and the right heart cavities after intravenous injection.